StockData
MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31

MapLight Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.00+0.30 (+3.90%)

Close on Oct 19, 2026

Market cap
$363.45M
P/E (TTM)
–
Dividend yield
–

SEC filings

16 of MapLight Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Quarterly report10-QJun 30, 2026Aug 13, 2026SEC EDGAR
Current report8-KAug 13, 2026Aug 13, 2026SEC EDGAR
Current report8-KJul 27, 2026Jul 27, 2026SEC EDGAR
Current report8-KJun 23, 2026Jun 24, 2026SEC EDGAR
Current report8-KJun 22, 2026Jun 22, 2026SEC EDGAR
Current report8-KJun 18, 2026Jun 18, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 14, 2026SEC EDGAR
Current report8-KMay 14, 2026May 14, 2026SEC EDGAR
Current report8-KApr 23, 2026Apr 29, 2026SEC EDGAR
Proxy statementDEF 14AJun 23, 2026Apr 29, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 26, 2026SEC EDGAR
Current report8-KMar 26, 2026Mar 26, 2026SEC EDGAR
Current report8-KJan 9, 2026Jan 9, 2026SEC EDGAR
Quarterly report10-QSep 30, 2025Dec 4, 2025SEC EDGAR
Current report8-KDec 4, 2025Dec 4, 2025SEC EDGAR
Current report8-KOct 26, 2025Oct 29, 2025SEC EDGAR